Comparison Between Uterine Artery Doppler and Placental Vascular Indices in Prediction of Preeclampsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-01

Study Completion Date

2022-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

• Preeclampsia is a multisystem disorder that can cause considerable maternal and fetal morbidity and mortality. Late preeclampsia (with delivery \>34 weeks) is more frequent and less serious than early preeclampsia (with delivery \<34 weeks). Poor early placentation has been especially associated with early disease. Early identification of women at risk of preeclampsia is currently a crucial aim of antenatal care since they may benefit from prophylactic treatment and increased surveillance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fetal Renal Artery Doppler in Patients With Preeclampsia

NCT06395974

Preeclampsia

RECRUITING

Prediction of Outcome in Severe Preeclampsia

NCT03871764

Leiden Factor V Deficiency,Preeclampsia Doppler Examination Palental Pathology

COMPLETED

Combined 3D Power Doppler Placental Volume and Vascular Flow Indices In the First Trimester of Pregnancy as Predictors Of Preeclampsia?.

NCT03399006

Preeclampsia

UNKNOWN

Vascular Endothelial Factor Gene Polymorphism in Preeclampsia

NCT03500588

Preeclampsia

COMPLETED

Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia

NCT02350036

Preeclampsia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* The introduction of three-dimensional (3D) ultrasound techniques, with the option of calculating placental volume and measuring vascular indices, has created an excellent opportunity to study early changes in the uteroplacental circulation space, which includes the maternal spiral arteries and the intervillous space. This technology may allow a more direct evaluation of the abnormal placentation process thought to herald the development of preeclampsia.
* The aim of this study was to assess the usefulness of placental volume and 3D vascular indices as reliable predictors of early preeclampsia in comparison to uterine artery Doppler

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

Pregnant women:

1. Age between 18-35 years
2. Parity: primigravidas and multiparas.
3. Have no history of preeclampsia or eclampsia.
4. Have no history of chronic hypertension.
5. Not diabetic.
6. Not have antiphospholipid syndrome.
7. Not have autoimmune disease such as SLE

ultrasound machine

Intervention Type DEVICE

Ultrasound machine with a vocal software

High risk group

Pregnant women with:

1. History of preeclampsia -Eclapmsia
2. Chronic hypertension
3. Diabetic
4. Antiphospholipid syndrome.
5. Autoimmune syndrome such as SLE.

ultrasound machine

Intervention Type DEVICE

Ultrasound machine with a vocal software

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ultrasound machine

Ultrasound machine with a vocal software

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A. Control group: Pregnant women:

1. Age between 18-35 years
2. Parity: primigravidas and multiparas.
3. Have no history of preeclampsia or eclampsia.
4. Have no history of chronic hypertension.
5. Not diabetic.
6. Not have antiphospholipid syndrome.
7. Not have autoimmune disease such as SLE.

B. High risk group: Pregnant women with:

1. History of preeclampsia -Eclapmsia
2. Chronic hypertension
3. Diabetic
4. Antiphospholipid syndrome.
5. Autoimmune syndrome such as SLE.